NO963746L - Isoksalin-forbindelser som inhibitorer for frigivning av TNF - Google Patents

Isoksalin-forbindelser som inhibitorer for frigivning av TNF

Info

Publication number
NO963746L
NO963746L NO963746A NO963746A NO963746L NO 963746 L NO963746 L NO 963746L NO 963746 A NO963746 A NO 963746A NO 963746 A NO963746 A NO 963746A NO 963746 L NO963746 L NO 963746L
Authority
NO
Norway
Prior art keywords
compounds
disease
inhibitors
tnf
isoxaline
Prior art date
Application number
NO963746A
Other languages
English (en)
Other versions
NO963746D0 (no
NO310496B1 (no
Inventor
Victoria L Cohan
Edward F Kleinman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO963746D0 publication Critical patent/NO963746D0/no
Publication of NO963746L publication Critical patent/NO963746L/no
Publication of NO310496B1 publication Critical patent/NO310496B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO19963746A 1994-03-09 1996-09-06 Anvendelse av isoksalin-forbindelser for fremstilling av et farmasöytisk preparat for å inhibere dannelse av TNF NO310496B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20912594A 1994-03-09 1994-03-09
PCT/IB1995/000078 WO1995024398A1 (en) 1994-03-09 1995-02-03 Isoxazoline compounds as inhibitors of tnf release

Publications (3)

Publication Number Publication Date
NO963746D0 NO963746D0 (no) 1996-09-06
NO963746L true NO963746L (no) 1996-11-06
NO310496B1 NO310496B1 (no) 2001-07-16

Family

ID=22777444

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19963746A NO310496B1 (no) 1994-03-09 1996-09-06 Anvendelse av isoksalin-forbindelser for fremstilling av et farmasöytisk preparat for å inhibere dannelse av TNF

Country Status (18)

Country Link
US (2) US5869511A (no)
EP (1) EP0749428B1 (no)
JP (1) JPH09505082A (no)
KR (1) KR100200449B1 (no)
CN (1) CN1143363A (no)
AT (1) ATE169009T1 (no)
AU (1) AU684887B2 (no)
CA (1) CA2185019C (no)
DE (1) DE69503769T2 (no)
DK (1) DK0749428T3 (no)
ES (1) ES2118557T3 (no)
FI (1) FI963510L (no)
IL (1) IL112847A (no)
MY (1) MY114667A (no)
NO (1) NO310496B1 (no)
NZ (1) NZ278667A (no)
WO (1) WO1995024398A1 (no)
ZA (1) ZA951909B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022977A (en) * 1997-03-26 2000-02-08 Dupont Pharmaceuticals Company Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids
US6150303A (en) * 1997-07-23 2000-11-21 Basf Aktiengesellschaft Substituted 3-phenylisoxazolines
WO1999014210A1 (en) * 1997-09-15 1999-03-25 Warner-Lambert Company Process for the preparation of substituted 5,6-dihydro-2h-pyran-2-ones
ATE315033T1 (de) * 1998-08-07 2006-02-15 Chiron Corp Subtituierte isoxazole derivate als estrogen rezeptor modulatore
EP1119568B1 (en) * 1998-10-09 2004-02-18 Janssen Pharmaceutica N.V. 4,5-dihydro-isoxazole derivatives and their pharmaceutical use
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
JP4195561B2 (ja) * 1999-09-17 2008-12-10 エルジー ケム インヴェストメント リミティッド カスパーゼインヒビター
KR100399361B1 (ko) * 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
GB0021776D0 (en) * 2000-09-05 2000-10-18 Arakis Ltd The treatment of inflammatory disorders
WO2002100332A2 (en) 2001-06-08 2002-12-19 Cytokine Pharmasciences, Inc. Isoxazoline compounds having mif antagonist activity
AU2002316384A1 (en) * 2001-06-26 2003-03-03 Photomed Technologies, Inc. Multiple wavelength illuminator
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
AU2003301903A1 (en) * 2002-11-06 2004-06-03 Bristol-Myers Squibb Company Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
RU2387646C2 (ru) * 2003-08-29 2010-04-27 Рэнбакси Лабораториз Лимитед Ингибиторы фосфодиэстеразы типа-iv
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
BRPI0508140B1 (pt) 2004-03-05 2015-03-17 Nissan Chemical Ind Ltd Composto benzamida substituída por isoxazolina da fórmula (1); da fórmula (2) substituído por 3,5-bis (aril substituído); da fórmula (4) substituída por alquinibenzeno ou um sal do mesmo; "pesticida, agroquímico, inseticida, parasiticida contendo como ingrediente ativo um ou mais composto benzamida substituída por isoxazolina e sal do mesmo"
BRPI0507818A (pt) * 2004-03-26 2007-07-10 Cytokine Pharmasciences Inc composto e métodos de inibição
KR101195351B1 (ko) 2004-06-17 2012-10-29 인피니티 디스커버리, 인코포레이티드 Ｂｃｌ 단백질과 결합 파트너와의 상호작용을 억제하는화합물 및 방법
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US20080009535A1 (en) * 2004-08-30 2008-01-10 Sarala Balachandran Inhibitors of phosphodiesterase type-IV
WO2006097273A1 (en) 2005-03-15 2006-09-21 Ganial Immunotherapeutics Inc. Compounds having immunomodulator activity
EP1997813B1 (en) 2006-03-10 2010-05-05 Nissan Chemical Industries, Ltd. Substituted isoxazoline compound and pest control agent
US7932052B1 (en) * 2006-07-24 2011-04-26 The Regents Of The University Of Michigan Use of methanobactin
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
WO2008035316A2 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
WO2008138516A1 (en) * 2007-05-09 2008-11-20 Ganial Immunoterapeutics Inc. (s,r)-3-phenyl-4,5 dihydro-5-isoxazole acetic acid-nitric oxide and use thereof as anti-cancer and antiviral agent
MY160002A (en) * 2009-02-10 2017-02-15 Celgene Corp Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
US20150064221A1 (en) 2012-04-17 2015-03-05 Niranjan Y. Sardesai Compounds having immunomudulator activity
CN102911131B (zh) * 2012-10-24 2014-10-29 中化蓝天集团有限公司 一种双键桥三氟甲基异噁唑类化合物、其制备方法及应用
US9815797B2 (en) * 2013-12-09 2017-11-14 Ucb Biopharma Sprl Fused bicyclic heteroaromatic derivatives as modulators of TNF activity
JP2023523779A (ja) * 2020-05-05 2023-06-07 ビーエーエスエフ ソシエタス・ヨーロピア 縮合イソオキサゾリン誘導体及び除草剤としてのそれらの使用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995048A (en) * 1975-10-20 1976-11-30 Sandoz, Inc. Isoxazolyl benzamides useful as tranquilizers and sleep-inducers
US4112108A (en) * 1976-12-06 1978-09-05 Sandoz, Inc. Isoxazolyl benzamides
JPS5512038A (en) * 1978-07-07 1980-01-28 Ube Industries Packing sack made of flat thread made from resin film
JPS55104273A (en) * 1979-02-05 1980-08-09 Sankyo Co Ltd 4-phenylisoxazole derivative and its preparation
CA1128526A (en) * 1979-10-05 1982-07-27 Cdc Life Sciences Inc. 3,4-diarylisoxazol-5-acetic acids
HU215433B (hu) * 1986-04-29 2000-05-28 Pfizer Inc. Eljárás új 2-oxo-5-fenil-pirimidin-származékok előállítására
US4892870A (en) * 1988-08-01 1990-01-09 Biofor, Ltd. Oxaza heterocycles and pharmaceutical compositions containing same
FR2639636B1 (fr) * 1988-11-30 1994-03-04 Novapharme Nouveaux composes heterocycliques a activite anticonvulsivante, procede de preparation et compositions therapeutiques les contenant
DE3914969A1 (de) * 1989-05-02 1990-11-08 Schering Ag 5-substituierte 3-arylisoxazol-derivate, deren herstellung und verwendung als schaedlingsbekaempfungsmittel
CA2017383A1 (en) * 1989-06-08 1990-12-08 Raymond R. Martodam Use of vanilloids for the treatment of respiratory diseases or disorders
KR920702621A (ko) * 1989-06-13 1992-10-06 스튜어트 알. 슈터 단핵세포 및/또는 마크로파지에 의한 인터루킨-1 또는 종양회사인자 생성의 억제
WO1991007177A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders
GB9007762D0 (en) * 1990-04-05 1990-06-06 Beecham Group Plc Novel compounds
US5051438A (en) * 1990-05-16 1991-09-24 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof, compositions and use
DE4016049A1 (de) * 1990-05-18 1991-11-21 Basf Ag 3-isoxazolylbenzylester, ihre herstellung und ihre verwendung
KR930703262A (ko) * 1990-11-06 1993-11-29 스튜어트 알. 슈터 이미다졸리디논 화합물
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
JP2702833B2 (ja) * 1991-10-09 1998-01-26 松下電器産業株式会社 レーザ加工装置
CZ283564B6 (cs) * 1993-11-26 1998-05-13 Pfizer Inc. 3-Aryl-2-isoxazolin-5-hydroxamové kyseliny a farmaceutické prostředky na jejich bázi

Also Published As

Publication number Publication date
CA2185019C (en) 2000-08-08
NZ278667A (en) 2000-12-22
DE69503769T2 (de) 1998-12-03
IL112847A (en) 1999-10-28
US6114367A (en) 2000-09-05
ES2118557T3 (es) 1998-09-16
MY114667A (en) 2002-12-31
FI963510A0 (fi) 1996-09-06
EP0749428B1 (en) 1998-07-29
JPH09505082A (ja) 1997-05-20
FI963510A7 (fi) 1996-09-06
WO1995024398A1 (en) 1995-09-14
AU1464795A (en) 1995-09-25
US5869511A (en) 1999-02-09
CN1143363A (zh) 1997-02-19
DE69503769D1 (de) 1998-09-03
NO963746D0 (no) 1996-09-06
IL112847A0 (en) 1995-06-29
AU684887B2 (en) 1998-01-08
EP0749428A1 (en) 1996-12-27
ATE169009T1 (de) 1998-08-15
DK0749428T3 (da) 1998-11-16
ZA951909B (en) 1996-09-09
NO310496B1 (no) 2001-07-16
MX9603975A (es) 1997-09-30
KR100200449B1 (ko) 1999-06-15
FI963510L (fi) 1996-09-06

Similar Documents

Publication Publication Date Title
FI963510A0 (fi) Isoksatsoliiniyhdisteitä TNF:n vapautumisen inhibiittoreina
CA2158632A1 (en) Catechol Diether Compounds as Inhibitors of TNF Release
FI945556A0 (fi) Tulehdustenvastaiset 3-aryyli-2-isoksatsoliinijohdannaiset
FI945557A0 (fi) Isoksatsoliiniyhdisteet tulehduksenvastaisina aineina
DK0730579T3 (da) Substituerede indoler som inhibitorer af phosphodiesterase-type-IV
DK1045690T3 (da) Benzensulfonamidinhibitorer af PDE-IV og deres terapeutiske anvendelse
WO2005019190A3 (en) (4 -amino -1,2, 5-oxadiazol-4-yl) -hetξroaromatic compounds useful as protein kinase inhibitors
NO982185L (no) Nye makrosykliske forbindelser som metalloproteinaseinhibitorer
HU9303423D0 (en) Catechin-diether-type pdeiv-inhibitors
WO2004094388A3 (en) Indazole derivatives as jnk inhibitors
WO2008071605A3 (en) Methods of treating inflammatory diseases
WO2003065987A3 (en) Granzyme b inhibitors
GB0320244D0 (en) Pyrazoles as inhibitors of tumour necrosis factor
ZA983704B (en) Phosphodiesterase 4-inhibiting diazepinoindolones.
GB0510584D0 (en) Organic compounds
WO2007102883A3 (en) Chemical compounds
GR3032272T3 (en) Indole carbamates as leukotriene antagonists
DK0752990T3 (da) Benzisothiazolderivater som inhibitorer af 5-lipoxygenasebiosyntese
TW202619730A (zh) Wdr5抑制劑、化合物、醫藥組合物、及其使用方法
MY112586A (en) Isoxazoline compounds as 5-lipoxygenase inhibitors
CL2008002853A1 (es) Compuestos derivados de piraziin quinolina sustituida, inhibidores de la migracion de macrofagos (mif); y su uso en el tratamiento de inflamacion, shock septico, artritis, cancer, trastornos autoinmunes e inhibicion de angiogenesis (divisional de la solicitud 1088-02)

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees